Phase 1 Study Testing Skin Patch Option for Alzheimer’s Patients Using Aricept

Phase 1 Study Testing Skin Patch Option for Alzheimer’s Patients Using Aricept
Transdermal (through the skin) delivery of Aricept (donepezil hydrochloride) may be as effective as the drug’s oral form, according to results of a pilot bioequivalence (BE) study conducted by Corium International. Aricept in tablet form is one of the only drugs approved for Alzheimer’s disease in the U.S. for patients with mild to moderate dementia. The drug acts by increasing the levels of the neurotransmitter acetylcholine. For family members and caregivers who cannot rely on Alzheimer’s patients to consistently take their medicine, taking a pill daily can pose a challenge. Also, taking Aricept orally may cause gastrointestinal side effects, including nausea, vomiting, and loss of appetite. The three-part Phase 1 BE  study (NCT02968719) is investigating how once-weekly Corplex Donepezil transdermal patches (in two patch sizes) compares with the oral tablet in drug delivery. The primary objective is to demonstrate that the daily oral and weekly patch methods shows similar steady-state pharmacokineti
Subscribe or to access all post and page content.